This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Francia, G. Articles by Kerbel, R. S. Search for Related Content PubMed PubMed Citation Articles by Francia, G. Articles by Kerbel, R. S.

Gene Expression Analysis of Tumor Spheroids Reveals a Role for Suppressed DNA Mismatch Repair in Multicellular Resistance to Alkylating Agents

Molecular and Cellular Biology Research, Sunnybrook and Women's College Health Sciences Centre, and Medical Biophysics, University of Toronto, Toronto, Ontario, Canada,¹ Genzyme Corporation, Framingham, Massachusetts,² Morphotek Inc., Exton, Pennsylvania³

Received 10 March 2004/ Accepted 12 April 2004

Drug resistance is a major obstacle in the successful treatment of cancer. Thus, elucidation of the mechanisms responsible is a critical first step in trying to prevent or delay such manifestations of resistance. In this regard, three-dimensional multicellular tumor cell spheroids are intrinsically more resistant to virtually all anticancer cytotoxic drugs than conventional monolayer cultures. We have employed the EMT-6 subline PC5T, which forms highly compact spheroids, and differential display to identify candidate genes whose expression differs between monolayer and spheroids. Approximately 5,000 bands were analyzed, revealing 26 to be differentially expressed. Analysis of EMT-6 tumor variants selected in vivo for acquired resistance to alkylating agents identified eight genes whose expression correlated with drug resistance in tumor spheroids. Four genes (encoding Nop56, the NADH SDAP subunit, and two novel sequences) were found to be down-regulated in EMT-6 spheroids and four (encoding 2-oxoglutarate carrier protein, JTV-1, and two novel sequences) were up-regulated. Analysis of the DNA mismatch repair-associated PMS2 gene, which overlaps at the genomic level with the JTV-1 gene, revealed PMS2 mRNA to be down-regulated in tumor spheroids, which was confirmed at the protein level. Analysis of PMS2^–/– mouse embryo fibroblasts confirmed a role for PMS2 in sensitivity to cisplatin, and DNA mismatch repair activity was found to be reduced in EMT-6 spheroids compared to monolayers. Dominant negative PMS2 transfection caused increased resistance to cisplatin in EMT-6 and CHO cells. Our results implicate reduced DNA mismatch repair as a determinant factor of reversible multicellular resistance of tumor cells to alkylating agents.

This article has been cited by other articles:

• Herrmann, R., Fayad, W., Schwarz, S., Berndtsson, M., Linder, S. (2008). Screening for Compounds That Induce Apoptosis of Cancer Cells Grown as Multicellular Spheroids. J Biomol Screen 13: 1-8 [Abstract]  
• Shen, D.-W., Liang, X.-J., Suzuki, T., Gottesman, M. M. (2006). Identification by Functional Cloning from a Retroviral cDNA Library of cDNAs for Ribosomal Protein L36 and the 10-kDa Heat Shock Protein that Confer Cisplatin Resistance. Mol. Pharmacol. 69: 1383-1388 [Abstract] [Full Text]  
• NICOLAIDES, N. C., EBEL, W., KLINE, B., CHAO, Q., ROUTHIER, E., SASS, P. M., GRASSO, L. (2005). Morphogenics as a Tool for Target Discovery and Drug Development. Ann. N. Y. Acad. Sci. 1059: 86-96 [Abstract] [Full Text]  
• Francia, G., Green, S. K., Bocci, G., Man, S., Emmenegger, U., Ebos, J. M.L., Weinerman, A., Shaked, Y., Kerbel, R. S. (2005). Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents. Molecular Cancer Therapeutics 4: 1484-1494 [Abstract] [Full Text]  
• Shahrzad, S., Quayle, L., Stone, C., Plumb, C., Shirasawa, S., Rak, J. W., Coomber, B. L. (2005). Ischemia-Induced K-ras Mutations in Human Colorectal Cancer Cells: Role of Microenvironmental Regulation of MSH2 Expression. Cancer Res. 65: 8134-8141 [Abstract] [Full Text]